

Global Inflammatory Bowel Disease (IBD) Market – Analysis By Disease Indication (Crohn’s Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)

<https://marketpublishers.com/r/G43FC79E9F11EN.html>

Date: April 2021

Pages: 260

Price: US\$ 2,400.00 (Single User License)

ID: G43FC79E9F11EN

Abstracts

EXECUTIVE SUMMARY

Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol consumption and cigarette smoking are likely to contribute towards the growth of the IBD market. Additionally, rise in investments in building a robust pipeline for IBD, increase in lifestyle-related risk factors and growing popularity of prebiotic and probiotic foods are likely to boost the growth of the global Inflammatory Bowel Disease market during the forecast period.

The North America region dominates the inflammatory bowel disease market. In North America, rising prevalence and incidence of IBD across the region is the major driving factor for Inflammatory Bowel Disease market. Moreover, an increasing number of cigarette-smokers in United States and significant funding in the IBD field in Canada is further estimated to boost the growth of the IBD market in the region. The IBD market in North America has remained at the forefront in terms of growth opportunities as well as developments in the field of Crohn’s Disease over the years. The region is likely to

continue to account for a significant piece of the revenue pie over the next few years as well, thanks to the presence of several pharmaceutical and biosciences companies and the presence of numerous leading players in the field of Crohn's Disease.

Additionally, increasing geriatric population base and prevalence of Ulcerative Colitis and Crohn's disease and also well-developed healthcare expenditure coupled with increased per capita healthcare expenditure across regions would enhance the growth of the inflammatory Bowel Disease market during the forecast period.

SCOPE OF THE REPORT

The report analyses Inflammatory Bowel Disease Market By Value.

The report analyses Inflammatory Bowel Disease Market By Disease Indication (Crohn's Disease, Ulcerative Colitis.)

The report further assesses the Inflammatory Bowel Disease Market By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Others.)

The report further assesses the Inflammatory Bowel Disease Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.)

The Global Inflammatory Bowel Disease has been analysed By Region (North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, France, Italy, Spain, United Kingdom, China, Japan, India)

The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions, Recent Industry Developments. Also, the attractiveness of the market has been presented By Region, By Disease Indication, By Drug Class and By Distribution Channel. Additionally, trends, drivers and challenges of the industry has been analysed in the report.

The companies analysed in the report include Johnson & Johnson, AbbVie Inc., Takeda, Pfizer, Roche, Celgene, GlaxoSmithKline, Novartis, UCB and Eli Lilly & Company.

The report presents the analysis of Inflammatory Bowel Disease Market for the

historical period of 2016-2020 and the forecast period of 2021-2026.

KEY TARGET AUDIENCE

Pharmaceutical Companies

Diagnostics Companies

Pharma R&D Organizations

Research and Consulting Firms

Government and Research Organisations

Contents

1. REPORT SCOPE AND METHODOLOGY

- 1.1 Scope of the Report
- 1.2 Research Methodology
- 1.3 Executive Summary

2. STRATEGIC RECOMMENDATIONS

3. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET: PRODUCT OUTLOOK

4. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET: AN ANALYSIS

- 4.1 Market Size, By Value, Year 2016-2026
- 4.2 COVID-19 Impact on Inflammatory Bowel Disease Market

5. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SEGMENTATION BY DISEASE INDICATION (BY VALUE)

- 5.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Disease Indication
- 5.2 Crohn's Disease - Market Size and Forecast (2016-2026)
- 5.3 Ulcerative Colitis - Market Size and Forecast (2016-2026)

6. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SEGMENTATION BY DRUG CLASS (BY VALUE)

- 6.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Drug Class
- 6.2 TNF Inhibitors - Market Size and Forecast (2016-2026)
- 6.3 Aminosalicylates - Market Size and Forecast (2016-2026)
- 6.4 Integrin Antagonists - Market Size and Forecast (2016-2026)
- 6.5 Others - Market Size and Forecast (2016-2026)

7. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SEGMENTATION BY DISTRIBUTION CHANNEL (BY VALUE)

- 7.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Distribution Channel

- 7.2 Hospital Pharmacies- Market Size and Forecast (2016-2026)
- 7.3 Retail Pharmacies - Market Size and Forecast (2016-2026)
- 7.4 Online Pharmacies - Market Size and Forecast (2016-2026)

8. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET: REGIONAL ANALYSIS

- 8.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Region

9. NORTH AMERICA INFLAMMATORY BOWEL DISEASE MARKET: AN ANALYSIS (2016-2026)

- 9.1 North America Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 9.2 North America Inflammatory Bowel Disease Market - Prominent Companies
- 9.3 Market Segmentation By Disease Indication (Crohn's Disease and Ulcerative Colitis.)
- 9.4 Market Segmentation By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists and Others.)
- 9.5 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.)
- 9.6 North America Inflammatory Bowel Disease Market: Country Analysis
- 9.7 Market Opportunity Chart of North America Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)
- 9.8 Competitive Scenario of North America- By Country
- 9.9 United States Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 9.10 United States Inflammatory Bowel Disease Market Leading Companies
- 9.11 United States Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.
- 9.12 Canada Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 9.13 Canada Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class and Distribution Channel.

10. EUROPE INFLAMMATORY BOWEL DISEASE MARKET: : AN ANALYSIS (2016-2026)

- 10.1 Europe Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value

- 10.2 Europe Inflammatory Bowel Disease Market - Prominent Companies
- 10.3 Market Segmentation By Disease Indication (Crohn's Disease, Ulcerative Colitis)
- 10.4 Market Segmentation By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Others.)
- 10.5 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.)
- 10.6 Europe Inflammatory Bowel Disease Market: Country Analysis
- 10.7 Market Opportunity Chart of Europe Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)
- 10.8 Competitive Scenario of Europe- By Country
- 10.9 France Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 10.10 France Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.
- 10.11 Germany Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 10.12 Germany Inflammatory Bowel Disease Market Leading Companies
- 10.13 Germany Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.
- 10.14 Italy Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 10.15 Italy Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.
- 10.16 Spain Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 10.17 Spain Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.
- 10.18 United Kingdom Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 10.19 United Kingdom Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.

11. ASIA PACIFIC INFLAMMATORY BOWEL DISEASE MARKET: : AN ANALYSIS (2016-2026)

- 11.1 Asia Pacific Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
- 11.2 Asia Pacific Inflammatory Bowel Disease Market - Prominent Companies
- 11.3 Market Segmentation By Disease Indication (Crohn's Disease and Ulcerative

Colitis.)

11.4 Market Segmentation By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Others.)

11.5 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.)

11.6 Asia Pacific Inflammatory Bowel Disease Market: Country Analysis

11.7 Market Opportunity Chart of Asia Pacific Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)

11.8 Competitive Scenario of Asia Pacific- By Country

11.9 China Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value

11.10 China Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.

11.11 India Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value

11.12 India Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.

11.13 Japan Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value

11.14 Japan Inflammatory Bowel Disease Market Leading Companies

11.15 Japan Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.

12. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET DYNAMICS

12.1 Global Inflammatory Bowel Disease Market Drivers

12.2 Global Inflammatory Bowel Disease Market Restraints

12.3 Global Inflammatory Bowel Disease Market Trends

13. MARKET ATTRACTIVENESS AND STRATEGIC ANALYSIS

13.1 Market Attractiveness

13.1.1 Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Disease Indication, By Value (Year-2026)

13.1.2 Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Drug Class, By Value (Year-2026)

13.1.3 Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Distribution Channel, By Value (Year-2026)

13.1.4 Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By

Region, By Value (Year-2026)

13.2 Strategic Analysis

13.2.1 Mergers and Acquisitions

13.2.2 Recent Industry Developments

14. COMPETITIVE LANDSCAPE

14.1 Market Share Analysis

15. INFLAMMATORY BOWEL DISEASE PIPELINE DEVELOPMENT

15.1 Emerging Therapies in Inflammatory Bowel Disease

16. COMPANY PROFILES (BUSINESS DESCRIPTION, FINANCIAL ANALYSIS, BUSINESS STRATEGY)

16.1 Johnson & Johnson

16.2 AbbVie Inc.

16.3 Takeda

16.4 Pfizer

16.5 Roche

16.6 Celgene

16.7 GlaxoSmithKline

16.8 Novartis

16.9 UCB

16.10 Eli Lilly & Company

List Of Figures

LIST OF FIGURES

Figure 1: Global Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 2: Etrasimod Global Forecast in UC (Ulcerative Colitis) , in USD Million

Figure 3: Etrasimod Global Forecast in CD (Chron's Disease) , in USD Million

Figure 4: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 5: Prevalence of Rheumatoid Arthritis , in million, from 2014 - 2019

Figure 6: Select pharmaceutical companies by number of inflammatory bowel disease drugs in development

Figure 7: Top future inflammatory bowel disease drugs by expected 2022 revenue, (in million U.S. dollars)

Figure 8: Diagnosed Incident Cases of Ulcerative Colitis, in both male and female, in all ages, 2016 and 2026

Figure 9: Diagnosed Incident Cases of Chron's Diseases, in both male and female, in all ages, 2019 and 2029

Figure 10: Global Inflammatory Bowel Disease Market, By Disease Indication, 2020, 2026

Figure 11: Global Inflammatory Bowel Disease Market- By Crohn's Disease, By Value (USD Million), 2016-2026

Figure 12: Global Inflammatory Bowel Disease Market- By Ulcerative Colitis, By Value (USD Million), 2016-2026

Figure 13: Global Inflammatory Bowel Disease Market, By Drug Class, 2020, 2026

Figure 14: Global Inflammatory Bowel Disease Market- By TNF Inhibitors, By Value (USD Million), 2016-2026

Figure 15: Global Inflammatory Bowel Disease Market- By Aminosalicylates, By Value (USD Million), 2016-2026

Figure 16: Global Inflammatory Bowel Disease Market- By Integrin Antagonists, By Value (USD Million), 2016-2026

Figure 17: Global Inflammatory Bowel Disease Market- By Others, By Value (USD Million), 2016-2026

Figure 18: Global Inflammatory Bowel Disease Market, By Distribution Channel, 2020, 2026

Figure 19: Global Inflammatory Bowel Disease Market- By Hospital Pharmacies, By Value (USD Million), 2016-2026

Figure 20: Global Inflammatory Bowel Disease Market- By Retail Pharmacies, By Value (USD Million), 2016-2026

Figure 21: Global Inflammatory Bowel Disease Market- By Online Pharmacies, By Value (USD Million), 2016-2026

Figure 22: Global Inflammatory Bowel Disease Market, By Region, 2020, 2026

Figure 23: North America Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 24: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 25: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 26: North America Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 27: North America Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 28: North America Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 29: North America Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016 2026

Figure 30: Market Opportunity Chart of North America Inflammatory Bowel Disease Market By Country, By Value, (Year-2026)

Figure 31: North America Inflammatory Bowel Disease Market, By Country, 2020, 2026

Figure 32: United States Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 33: United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 34: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 35: Ulcerative Colitis diagnosed & treated patients (in K) in the US in 2020 & 2030

Figure 36: Crohn's Disease diagnosed & treated patients (in K) in the US in 2020 & 2030

Figure 37: % of U.S. inflammatory bowel disease (IBD) patients that experienced select symptoms associated with IBD, 2019

Figure 38: United State Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 39: United States Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 40: United States Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 41: United States Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 42: Canada Inflammatory Bowel Disease Market Size, By Value, 2016-2026

(USD Million)

Figure 43: Healthcare Expenditure, as a percentage of GDP, Canada, 2019

Figure 44: Canada Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 45: Canada Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 46: Canada Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 47: Canada Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 48: Europe Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 49: Europe Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 50: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 51: Pharmaceutical market value in top ten European countries in 2018, (in million euros)

Figure 52: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 53: Europe Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 54: Europe Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 55: Europe Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 56: Market Opportunity Chart of Europe Inflammatory Bowel Disease Market- By Country, By Value (Year-2026)

Figure 57: Europe Inflammatory Bowel Disease Market, By Country, 2020, 2026

Figure 58: France Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 59: Total revenue of the French drug market from 2010 to 2019, in maker pre-tax price, (in million euros)

Figure 60: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 61: France Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 62: France Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 63: France Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 64: Germany Inflammatory Bowel Disease Market Size, By Value, 2016-2026

(USD Million)

Figure 65: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 66: Germany Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 67: Germany Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 68: Germany Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 69: Germany Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 70: Italy Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 71: Public Health Expenditure, in Italy, 2015 - 2019, (Euro Million)

Figure 72: Number of Individuals with Chronic Disease, By Type, 2018, (1000 Individuals)

Figure 73: Annual growth rate of the pharmaceutical market in Italy from 2017 to 2022

Figure 74: Italy Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 75: Italy Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 76: Italy Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 77: Italy Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 78: Spain Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 79: Pharmaceutical Spending (USD Per Capita), in Spain, 2016 - 2019

Figure 80: Number of pharmacies in Spain from 2007 to 2019

Figure 81: Spain Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 82: Spain Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 83: Spain Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 84: United Kingdom Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 85: United Kingdom Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 86: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 87: Value size of the digital health industry in the United Kingdom (UK) in 2014 and 2018, (in million GBP)

Figure 88: Market Share of Top Pharma Companies in United Kingdom, in 2018

Figure 89: United Kingdom Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 90: United Kingdom Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 91: United Kingdom Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 92: Asia Pacific Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 93: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 94: Asia Pacific Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 95: Projected Pharmaceuticals Sales, in USD Billion, in selected Asia Pacific countries

Figure 96: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 97: Asia Pacific Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 98: Asia Pacific Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 99: Asia Pacific Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 100: Market Opportunity Chart of Asia Pacific Inflammatory Bowel Disease Market- By Country, By Value (Year-2026)

Figure 101: Asia Pacific Inflammatory Bowel Disease Market, By Country, 2020, 2026

Figure 102: China Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 103: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 104: China Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 105: China Online Healthcare Market in RMB Billions

Figure 106: Market Size of Biotech in China, from 2010 - 2018, in RMB Billion

Figure 107: China Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 108: China Inflammatory Bowel Disease Market- By Drug Class, By Value (USD

Million), 2016-2026

Figure 109: China Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 110: India Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 111: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 112: India Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 113: India Healthcare Sector Revenue Share

Figure 114: Sale of India Pharma Companies in Dec 2019, (Rs Crore)

Figure 115: India Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 116: India Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 117: India Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 118: Japan Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)

Figure 119: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 120: Japan Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 121: Japan Inflammatory Bowel Disease Market- By Disease Indication, By Value (USD Million), 2016-2026

Figure 122: Japan Inflammatory Bowel Disease Market- By Drug Class, By Value (USD Million), 2016-2026

Figure 123: Japan Inflammatory Bowel Disease Market- By Distribution Channel, By Value (USD Million), 2016-2026

Figure 124: Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Disease Indication, By Value (Year 2026)

Figure 125: Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Drug Class, By Value (Year 2026)

Figure 126: Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Distribution Channel, By Value (Year 2026)

Figure 127: Market Attractiveness Chart of Global Inflammatory Bowel Disease Market By Region, By Value, (Year-2026)

Figure 128: Global Inflammatory Bowel Disease company market share (%), 2020

Figure 129: Johnson & Johnson Annual Sales Revenue (USD Million), 2016-2020

Figure 130: Johnson & Johnson Annual Net Income/Loss (USD Million), 2016-2020

Figure 131: Johnson & Johnson Sales Revenue Split, By Business Segment (%),

FY2020

Figure 132: Johnson & Johnson Sales Revenue Split, By Geography Segment (%),
FY2020

Figure 133: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020

Figure 134: AbbVie Inc. Annual Net Income/Loss (USD Million), 2016-2020

Figure 135: AbbVie Inc. Sales Revenue Split, By Business Segment (USD Million),
FY2020

Figure 136: AbbVie Inc. Sales Revenue Split, By Geography Segment (USD Million),
FY2020

Figure 137: Takeda Annual Sales Revenue (USD Million), 2015-2018

Figure 138: Takeda Annual Net Income/Loss (USD Million), 2015-2018

Figure 139: Takeda Sales Revenue Split, By Business Segment (USD Million), FY2018

Figure 140: Takeda Sales Revenue Split, By Geography Segment (%), FY2018

Figure 141: Pfizer Annual Sales Revenue (USD Million), 2016-2020

Figure 142: Pfizer Annual Net Income/Loss (USD Million), 2016-2020

Figure 143: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020

Figure 144: Roche Annual Sales Revenue (USD Million), 2016-2020

Figure 145: Roche Annual Net Income/Loss (USD Million), 2016-2020

Figure 146: Roche Sales Revenue Split, By Business Segment (%), FY2020

Figure 147: Roche Sales Revenue Split, By Geography Segment (%), FY2020

Figure 148: Celgene Annual Sales Revenue (USD Million), 2014-2018

Figure 149: Celgene Annual Net Income/Loss (USD Million), 2014-2018

Figure 150: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020

Figure 151: GlaxoSmithKline Annual Net Income/Loss (USD Million), 2016-2020

Figure 152: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020

Figure 153: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%),
FY2020

Figure 154: Novartis Annual Sales Revenue (USD Million), 2016-2020

Figure 155: Novartis Annual Net Income/Loss (USD Million), 2016-2020

Figure 156: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020

Figure 157: Novartis Sales Revenue Split, By Geography Segment (%), FY2020

Figure 158: UCB Annual Sales Revenue (USD Million), 2016-2020

Figure 159: UCB Annual Net Income/Loss (USD Million), 2016-2020

Figure 160: UCB Sales Revenue Split, By Geography Segment (%), FY2020

Figure 161: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020

Figure 162: Eli Lilly and Company Annual Net Income/Loss (USD Million), 2016-2020

Figure 163: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD
Million), FY2020

Figure 164: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%),

FY2020

List Of Tables

LIST OF TABLES

Table A: IBD Opportunity- Target Patient Population Sizes

Table B: Key IBD Drugs Revenue in USD Million in 2019 and 2018

Table C: Approved biologics/ novel orals in UC (Ulcerative Colitis)

Table D: Approved biologics/ novel orals in CD (Chron's Disease)

Table E: Phase III IBD drugs In development

Table F: Prominent Inflammatory Bowel Disease Companies operating in North America

Table G: Market share for the 10 top-selling originator biologics in Canada, 2018

Table H: Prominent Inflammatory Bowel Disease Companies operating in Europe

Table I: Prominent Inflammatory Bowel Disease companies operating in Asia Pacific

Table J: Overview of key pipeline assets in development for UC (Ulcerative Colitis)

Table K: Overview of key pipeline assets in development for CD (Chron's Disease)

I would like to order

Product name: Global Inflammatory Bowel Disease (IBD) Market – Analysis By Disease Indication (Crohn's Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)

Product link: <https://marketpublishers.com/r/G43FC79E9F11EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G43FC79E9F11EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970